* Sweetened offer values Evonik at €11.18 billion, or €24
per share
* Evonik asks BASF management to elaborate on bid's
rationale
* BASF says it made extensive commitments on employees and
sites
(Adds BASF statement in paragraph 5, details and background
throughout)
By Matthias Inverardi
DUESSELDORF, Oct 30 (Reuters) - German chemicals group
Evonik EVKn.DE said on Friday that BASF's BASFn.DE sweetened
takeover offer was not enough to persuade it to start formal
deal talks, but it has asked the suitor's management to
elaborate on the rationale for its bid.
"The Executive Board remains focused on its strategic
direction and further development of Evonik as an independent
company," it said in a statement.
According to a person familiar with the matter, Evonik
remains unconvinced by the industrial logic behind a merger of
the two groups.
BASF last week made an improved offer worth €11.18 billion
($12.5 billion) or €24 per share, for a takeover which its CEO
Markus Kamieth said would offer a "strong German response to
global competition," while stressing BASF would not overpay.
EVONIK REJECTED BID IN SEPTEMBER
BASF, one of the world's largest chemical companies by
revenue, improved its bid last week from an original €22.15 per
share, which Evonik had rejected in September.
On Friday, BASF expressed surprise that Evonik was not
prepared to consider its "attractive offer" and "extensive
commitments made regarding employees and sites."
"However, we acknowledge Evonik's willingness to engage in
discussions," it said in a statement.
Evonik's products include high-tech plastics and feed
additives, as well as ingredients for coatings and household
products. BASF makes engineering plastics, superabsorbent
polymers, vitamins and chemicals for industrial uses.
BASF has said it would honour existing agreements to
preserve jobs made by Evonik in the event of an acquisition and
warned that more painful takeover approaches from abroad were
looming.
People familiar with the matter have told Reuters that
Evonik itself had been exploring an acquisition of US rival
Ashland ASH.N for some time.
Evonik CEO Christian Kullmann, who went on medical leave in
August, previously said there would be consolidation in the
industry and Evonik wants to play an active role in it.
(Reporting by Matthias Inverardi; Writing by Ludwig Burger
and Matthias Williams; Editing by Kirsti Knolle and David
Holmes)
((ludwig.burger@thomsonreuters.com))